Baseline parameters of CLL patients (N=52).
| Male, N (%) | 35 (67.3%) |
| Female, N (%) | 17 (32.7%) |
| Male:female | 2:1 |
| Median age (range), yr | 65 (43–88) |
| <60 yr, N (%) | 15 (28.8%) |
| ≥60 yr, N (%) | 37 (71.2%) |
| Incidental lymphocytosis | 9 (17%) |
| Fatigue | 19 (37%) |
| B-symptoms | 7 (13.5%) |
| Hepatomegaly | 14 (27.0%) |
| Splenomegaly, N (%) | 20 (38.5%) |
| Lymphadenopathy, N (%) | 28 (53.8%) |
| <3 groups involved | 09 (32.1%) |
| 3 or more groups involved | 19 (67.9%) |
| ECOG performance status | |
| 0, N (%) | 16 (30.8%) |
| 1, N (%) | 28 (53.8%) |
| 2/3, N (%) | 08 (15.4%) |
| Hemoglobin, median (g/dL) | 12.4 (5.0–16.6) |
| Total leucocyte count, median (×109/L) | 57.7 (18.0–307.8) |
| Absolute lymphocyte count, median (×109/L) | 52.0 (7.6–292.4) |
| Platelet count, median (×109/L) | 176.5 (46.0–449.0) |
| Smudge cells, median (%) | 32 (5–126) |
| Lactate dehydrogenase (LDH) (U/L) | |
| Within normal range, N (%) | 31 (59.6%) |
| Elevated (>1×upper limit of normal), N (%) | 16 (30.8%) |
| Missing data, N (%) | 5 (9.6%) |
| β2-microglobulin (mg/L), median | 4.7 (0.89–16.5) |
| Within normal range, N (%) | 4 (7.7%) |
| Elevated, N (%) | 27 (51.9%) |
| Missing data, N (%) | 21 (40.4%) |
| Modified Rai stage | |
| Low, N (%) | 16 (30.8%) |
| Intermediate, N (%) | 23 (44.2%) |
| High, N (%) | 13 (25.0%) |
| Binet stage | |
| A, N (%) | 29 (55.8%) |
| B, N (%) | 10 (19.2%) |
| C, N (%) | 13 (25.0%) |
| Atypical immunophenotypic features in different combinations identified in the study cohort | |
| CD23 weak or absent expression, N (%) | 7 (13.5%) |
| Bright CD20 expression, N (%) | 5 (9.6%) |
| Bright expression of SIgλ/SIgκ, N (%) | 12 (23.1%) |
Blood Res 2020;55:131~138 https://doi.org/10.5045/br.2020.2020080
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd